Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 1/20 | 0.71 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.58 |
| ▸ | SLC7A5 | Q01650 | 4/20 | 0.57 |
| ▸ | ALPI | P09923 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.57 |
| ▸ | XIAP | P98170 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | NOS3 | P29474 | 2/20 | 0.54 |
| ▸ | NOS1 | P29475 | 2/20 | 0.54 |
| ▸ | NOS2 | P35228 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| M-Fluorophenylalanine SCHEMBL42949 | 0.91 | SLC1A1 (0.69) | GRIA2SLC1A1SLC7A5ALPIPKM | |
| M-Fluorophenylalanine SCHEMBL29424682 | 0.91 | SLC1A1 (0.69) | GRIA2SLC1A1SLC7A5ALPIPKM | |
| M-Fluorophenylalanine SCHEMBL42948 | 0.91 | SLC1A1 (0.69) | GRIA2SLC1A1SLC7A5ALPIPKM | |
| M-Fluorophenylalanine SCHEMBL29580111 | 0.91 | SLC1A1 (0.69) | GRIA2SLC1A1SLC7A5ALPIPKM | |
| M-Fluorophenylalanine SCHEMBL288728 | 0.91 | SLC1A1 (0.69) | GRIA2SLC1A1SLC7A5ALPIPKM | |
| SCHEMBL29217053 | 0.91 | GRIA2 (0.84) | GRIA2SLC7A5ALPIPKMPTGS1 | |
| SCHEMBL944210 | 0.91 | GRIA2 (0.84) | GRIA2SLC7A5ALPIPKMPTGS1 | |
| SCHEMBL31688962 | 0.90 | GRIA2 (0.69) | GRIA2SLC7A5ALPIPKMPTGS1 | |
| M-Fluorophenylalanine SCHEMBL21057062 | 0.89 | SLC1A1 (0.68) | GRIA2SLC1A1SLC7A5ALPIPKM | |
| M-Fluorophenylalanine SCHEMBL21057063 | 0.89 | SLC1A1 (0.68) | GRIA2SLC1A1SLC7A5ALPIPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | claimed |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | BCAT1, BCAT2, PELP1 | GRIA2 1319/4885SLC1A1 305/4885SLC7A5 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.